Back to search

Article

Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of <i>Aureobasidium pullulans</i> produced biological response modifier β-glucan (BRMG)

2022-11-17

Abstract excerpt

Recent advances in the management of Duchenne Muscular Dystrophy (DMD), such as exon skipping therapy, have reached a clinical stage, and although gene therapy is in clinical trials, the outcome at its best is still considered suboptimal to yield clinically discernible progress. In this study, we evaluated a novel N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG) for it...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c947fef1-d415-5b9d-b823-6bb68b4da09e
DOI
10.1101/2022.11.17.516628
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of <i>Aureobasidium pullulans</i> produced biological response modifier β-glucan (BRMG)DOI 10.1101/2022.11.17.516628
Efficacy of N-163 strain of<i>Aureobasidium pullulans</i>-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trialSemantic proximity
Reduction in myocardial fibrosis in MDX mice on oral consumption of <i>Aureobasidium Pullulans</i> produced Neu REFIX Beta-glucans; holds potential as an adjuvant in managing post-transplantation organ fibrosisSemantic proximity
Enhanced expression of Dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including Diaphragm of <i>mdx</i> mice after oral administration of Neu REFIX Beta 1,3-1,6 glucanSemantic proximity
Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical studySemantic proximity
Muscular Dystrophies and Therapeutic Potential of Medicinal PlantsSemantic proximity
Nutritional intervention with cyanidin hinders the progression of muscular dystrophy.Semantic proximity
The BALB/c.mdx62 mouse exhibits a dystrophic muscle pathology and is a model of Duchenne muscular dystrophy.Semantic proximity
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscleSemantic proximity
Low dose resveratrol promotes hypertrophy in wildtype skeletal muscle and reduces damage in skeletal muscle of exercised <i>mdx</i> miceSemantic proximity
Humanization of the mdx Mouse Phenotype for Duchenne Muscular Dystrophy Modeling: A Metabolic Perspective.Semantic proximity
Treatment with Lactobacillus delbruckii inhibits hypertrophic scar fibrosisSemantic proximity
A Novel Probiotic Strain Exerts Therapeutic Effects on Mouse Model of Multiple Sclerosis by Altering The Expression of Inflammasome and IDO Genes and Modulation of T Helper Cytokine ProfileSemantic proximity
Select a neighboring publication to make it the new centre.